Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Caitlin E. Cox

October 31, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

News Daily News

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Michael O'Riordan

September 17, 2018

News Daily News

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Yael L. Maxwell

August 03, 2018

News Daily News

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

L.A. McKeown

July 10, 2018

News Daily News

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

Todd Neale

June 21, 2018

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Daily News

‘Nontraditional’ CAC, CRP, or ABI Risk Tools Not Recommended, Says USPSTF

Shelley Wood

January 17, 2018

Advertisement

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

‘Nontraditional’ CAC, CRP, or ABI Risk Tools Not Recommended, Says USPSTF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content